TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)

Sponsor
Zhongming Qiu
Study ID
NCT07355257
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Inflammatory Myopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Telitacicept 240mg — DRUG
    On the basis of the original foundational medication regimen, add Telitacicept 240mg administered via subcutaneous injection once a week for a total of 12 weeks.

Study Details

The goal of this clinical trial is to evaluate the efficacy of Telitacicept in the treatment of inflammatory myopathy in patients with inflammatory diseases. The main question it aims to answer is: the safety and effectiveness of Telitacicept in treating inflammatory myopathy.

Key Dates

Start date
Feb 2, 2026
Status verified
Jan 2026
Primary completion
Dec 30, 2026
Completion
Mar 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental: Treatment group

Primary Outcome Measure

Physician's Global Assessment (PGA) Score [ Time Frame: From enrollment to the end of treatment at 12 weeks ]

Central Contacts

Related Studies